Patient Experience in Early-Stage Parkinson ’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment
ConclusionPatient experiences in early-stage PD are complex and wide-ranging, and the currently available patient-reported outcome (PRO) instruments do not evaluate many early-stage PD concepts such asfunctional slowness, fine motor skills, and subtle gait abnormalities. The development of a new PRO instrument, created in conjunction with people with PD, that fully assesses symptoms and the experience of living with early-stage PD, is required. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 1, 2022 Category: Neurology Source Type: research
Long-Term Clinical Experience with Directional Deep Brain Stimulation Programming: A Retrospective Review
ConclusionOver a 36-month time period 39 –68% of patients with PD and 50–72% of patients with ET had at least one lead programmed directionally in order to either improve symptom control or reduce side effects, an option not available with conventional omnidirectional stimulation. Initially directional electrodes were used in ET more f requently than PD, likely because of the less complex nature of programming for a monosymptomatic disorder. However, over time this shifted as we gained directional experience and sought solutions to reduce worsening symptoms. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 1, 2022 Category: Neurology Source Type: research
Clinical Staging of Alzheimer ’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System
ConclusionsWe found higher concordance between clinician ’s assessment and test-based assessment of Alzheimer’s disease severity in dementia specialty clinics. Discordance is especially high for the subjectively assessed mild AD cohort where objective assessments showed a higher severity level in 40% of notes. These data indicate a critical need for i mproved understanding of clinical assessments and decision-making to identify appropriate patients for anti-amyloid therapy. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 1, 2022 Category: Neurology Source Type: research
The Potential Economic Value of Lecanemab in Patients with Early Alzheimer ’s Disease Using Simulation Modeling
ConclusionThe early model predicted that lecanemab would potentially improve long-term health outcomes and reduce formal and informal care costs, resulting in a range of VBPs that reflect the value of lecanemab to society. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 20, 2022 Category: Neurology Source Type: research
Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial
ConclusionIn the Chinese population, lasmiditan was better than placebo for both primary endpoints and key secondary endpoints with an acceptable safety profile. No new safety signals were detected in the Chinese population. These findings are generally consistent with those observed in the CENTURION study published data and the established product profile.Trial Registration NumberNCT03670810. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 17, 2022 Category: Neurology Source Type: research
Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
ConclusionA considerable proportion of patients did not receive DMT, suggesting that patients with early-stage MS may lose the opportunity to improve their prognosis through early intervention with DMT. Among patients with a longer duration since the first diagnosis, fewer treatment choices may be available despite the larger clinical and treatment burden. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 17, 2022 Category: Neurology Source Type: research
Opicapone as an Add-on to Levodopa in Patients with Parkinson ’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
The objective of the EPSILON study is to investigate the efficacy of opicapone (OPC; a third-generation, once-daily COMT inhibitor) in enhancing the clinical benefit of levodopa in patients in earlier stages of PD, without end-of-dose motor fluctuations.MethodsEPSILON is a phase III, double-blind, randomised, placebo-controlled and parallel-group study, designed to evaluate the efficacy and safety of OPC as add-on to levodopa/DDC inhibitor therapy in patients with early PD who do not exhibit signs of motor complications. Eligible patients will be randomised (1:1) to recei ve OPC 50 mg or placebo, in addition to their ex...
Source: Neurology and Therapy - June 16, 2022 Category: Neurology Source Type: research
Outcomes of Endovascular Therapy in Young Patients with Acute Basilar Artery Occlusion: A Substudy of BASILAR Registry Study
ConclusionYoung patients with BAO had better clinical outcomes after EVT than old patients. Predictors of clinical outcomes in young patients undergoing EVT included baseline NIHSS score, pc-ASPECTS, and sex.Trial RegistrationClinical Trial Registration-URL: ChiCTR180001475 (www.chictr.org.cn). (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 16, 2022 Category: Neurology Source Type: research
Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
ConclusionAtogepant is an efficacious and overall well-tolerated treatment for the prevention of episodic migraine in adults. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 15, 2022 Category: Neurology Source Type: research
Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes
ConclusionThe co-occurrence of fatigue, cognitive impairment, depression, and pain in MS appears to be associated with a common set of etiological factors, namely neuroanatomical changes, pro-inflammatory cytokines, dysregulation of monoaminergic pathways, and a hyperactive HPA axis. This association of symptoms and biological processes has important implications for disease management strategies and, eventually, could help find a common therapeutic pathway that will impact both inflammation and neuroprotection. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 9, 2022 Category: Neurology Source Type: research
Burden Among Caregivers of Pediatric Patients with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: A Cross-Sectional Study
ConclusionsThe burden among caregivers of pediatric patients with NF1-PN is considerable and underscores an unmet need for better disease management. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 9, 2022 Category: Neurology Source Type: research
Therapeutic Decision-Making Under Uncertainty in the Management of Spinal Muscular Atrophy: Results From DECISIONS-SMA Study
ConclusionsPediatric neurologists managing patients with SMA were optimistic regarding treatment improvement in cases with early diagnosis, but had lower expectations when treatment delays and advanced patient age were present. Low aversion to ambiguity, low expectation of treatment benefits, and lower clinical experience were more likely to make suboptimal decisions, resulting in lack of treatment initiation, escalation, and TI. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 3, 2022 Category: Neurology Source Type: research
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
ConclusionIn this large cohort, we confirm previous data about cladribine effectiveness on disease activity and disability worsening and provide information on response predictors that might inform therapeutic choices. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 2, 2022 Category: Neurology Source Type: research
The Humanistic and Economic Burden of Alzheimer's Disease
AbstractAlzheimer ’s disease (AD) is the leading cause of cognitive impairment and dementia in older individuals (aged ≥ 65 years) throughout the world. As a result of these progressive deficits in cognitive, emotional, and physical function, AD dementia can cause functional disability and loss of independen ce. To gain a deeper understanding of the recent literature on the burden of AD, including that of mild cognitive impairment (MCI) due to AD, we conducted a comprehensive targeted review of the PubMed-indexed literature (2014 to 2021) to examine the humanistic and economic burden of AD (including MC I) in Nort...
Source: Neurology and Therapy - May 12, 2022 Category: Neurology Source Type: research
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson ’s Disease: Clinical Trial Post Hoc Analyses
ConclusionCLES-treated patients experienced a more rapid onset of ON-woTD after waking and greater consistency of ON-woTD throughout their waking day than IR –CL-treated patients. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 12, 2022 Category: Neurology Source Type: research
